SCS Capital Management LLC decreased its position in Astrazeneca Plc (NYSE:AZN – Free Report) by 82.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 32,056 shares of the company’s stock after selling 151,551 shares during the period. SCS Capital Management LLC’s holdings in Astrazeneca were worth $5,626,000 at the end of the most recent quarter.
Several other hedge funds have also made changes to their positions in AZN. Bank of Montreal Can grew its stake in shares of Astrazeneca by 344.6% in the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after buying an additional 2,695,793 shares during the period. Holocene Advisors LP grew its stake in shares of Astrazeneca by 41.8% in the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock valued at $470,232,000 after buying an additional 1,807,565 shares during the period. Bank Julius Baer & Co. Ltd Zurich lifted its holdings in shares of Astrazeneca by 11,190.9% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock worth $317,107,000 after acquiring an additional 1,790,874 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in shares of Astrazeneca by 64.8% in the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock worth $264,373,000 after acquiring an additional 1,487,662 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Astrazeneca by 4.7% in the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after acquiring an additional 1,461,786 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. restated a “buy” rating on shares of Astrazeneca in a report on Monday. Morgan Stanley restated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. Weiss Ratings assumed coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating on the stock. Finally, Barclays restated a “buy” rating on shares of Astrazeneca in a report on Monday. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.
Astrazeneca Price Performance
Astrazeneca stock opened at $179.90 on Tuesday. The firm has a market cap of $279.01 billion, a PE ratio of 27.01, a price-to-earnings-growth ratio of 1.48 and a beta of 0.25. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The company’s 50 day moving average is $191.20 and its two-hundred day moving average is $184.28.
Astrazeneca (NYSE:AZN – Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The company had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, research analysts expect that Astrazeneca Plc will post 10.26 EPS for the current fiscal year.
About Astrazeneca
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
Featured Articles
- Five stocks we like better than Astrazeneca
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
